Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…
Browsing: Chronic Myelogenous Leukemia
iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS,…
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…
iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD…
Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN…
Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks…
Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks…
Nobuko Hijiya, MD, Pediatric Hematology-Oncology at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children’s Hospital speaks about A…
Nobuko Hijiya, MD, Pediatric Hematology-Oncology at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children’s Hospital speaks about A…
Gianantonio Rosti, MD from the Università di Bologna speaks about OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses…
Jorge Cortes, MD, Director of the Georgia Cancer Center discusses the ASCO 2021 Abstract – OPTIC primary analysis: A dose-optimization…
Jorge Cortes, MD, Director at the Georgia Cancer Center discusses U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG®…
Athena Kritharis, MD — she’s a Hematologist/Oncologist in the Hematologic Malignancies Program at Robert Wood Johnson University Hospital and Rutgers…
Andreas Hochhaus, MD of the Klinik für Innere Medizin II, Jena, Germany speaks about the ASH 2020 abstract – LBA-4…
Joshua Zeidner, MD from the University of North Carolina, Lineberger Comprehensive Cancer Center discusses the ASH 2020 abstract – 2191…
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…
Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440)…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440)…
Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in…
Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in…
Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. … A team of researchers…
Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. _____________ A team of researchers…
Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai provides perspective on how oral therapies will impact…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai elaborates on the current approaches to treating elderly…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai offers opinion on how the treatment of myelodysplastic…
Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib: what is next for research?
Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib.
Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): what’s next in…
Dr. Susan Branford
Dr. Jorge Cortez
Dr. Ekaterina Chelsheva
Dr. Carla Bouqimpani
Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College…
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here,…
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the…
Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline…
An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of…
Speaking from the American Society of Oncology (ASCO) 2018, held in Chicago, IL, Michael Mauro, MD, of Memorial Sloan Kettering…
The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML),…
Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers.…
Richard Clark, MA, MD, MRCP, FRCPath, of the Royal Liverpool University Hospital, Liverpool, UK, presented the final results of the…
With the many new second generation therapies for chronic myeloid leukemia (CML), there is some debate as to which therapy…
The aims of treatment for chronic myeloid leukemia (CML) have changed in recent years, as explained here by Susanne Saussele,…
Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD,…